A5036242687- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Vascular Anomalies and Treatments
- Liver Disease and Transplantation
- Heart Failure Treatment and Management
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Transplantation: Methods and Outcomes
- Respiratory Support and Mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Venous Thromboembolism Diagnosis and Management
- COVID-19 Clinical Research Studies
- Sarcoidosis and Beryllium Toxicity Research
- Organ Transplantation Techniques and Outcomes
- Congenital Heart Disease Studies
- Autoimmune and Inflammatory Disorders Research
- Cardiac Arrhythmias and Treatments
- Long-Term Effects of COVID-19
- Systemic Sclerosis and Related Diseases
- Lung Cancer Treatments and Mutations
- COVID-19 and healthcare impacts
- Cardiac Valve Diseases and Treatments
- Obstructive Sleep Apnea Research
- Thermal Regulation in Medicine
- Intensive Care Unit Cognitive Disorders
Inserm
2016-2025
Hypertension pulmonaire : physiopathologie et innovation thérapeutique
2015-2025
Hôpital Marie Lannelongue
2017-2025
Bicêtre Hospital
2016-2025
Assistance Publique – Hôpitaux de Paris
2014-2025
Université Paris-Saclay
2016-2025
Imperial College London
2023-2024
European Research Services
2023
Société Française de Médecine Vasculaire
2023
Centre Hospitalier Universitaire de Poitiers
2014-2023
Current European guidelines recommend periodic risk assessment for patients with pulmonary arterial hypertension (PAH). The aim of our study was to determine the association between number low-risk criteria achieved within 1 year diagnosis and long-term prognosis. Incident idiopathic, heritable drug-induced PAH 2006 2016 were analysed. present at first re-evaluation assessed: World Health Organization (WHO)/New York Heart Association (NYHA) functional class I or II, 6-min walking distance...
Background: Hemodynamic variables such as cardiac index and right atrial pressure have consistently been associated with survival in pulmonary arterial hypertension (PAH) at the time of diagnosis. Recent studies suggested that compliance may also predict prognosis PAH. The prognostic importance hemodynamic values achieved after treatment initiation is less well established. Methods: Our objective was to evaluate clinical during follow-up, including compliance, initial management We evaluated...
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate long-term of patients with PAH categorized according to strategy. Methods: A retrospective analysis incident idiopathic, heritable, or anorexigen-induced enrolled French Pulmonary Hypertension Registry (January 2006 December 2018) was conducted. Survival assessed strategy: monotherapy, dual therapy, triple-combination therapy (two...
Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of achieve low status most remaining Our aim was to validate a four-stratum approach categorising intermediate-low, intermediate-high risk, proposed by the Comparative, Prospective Registry Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators.We evaluated incident from French PAH and applied method at baseline first...
Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated (S-APH) are limited. Clinical and haemodynamic data from newly diagnosed patients severe S-APH (mean artery pressure (mPAP) >35 mmHg or mPAP 25–35 cardiac index <2.5 L·min −1 ·m −2 ) were collected French Pulmonary Hypertension Registry between 2004 2015. Data 126 analysed (mean± sd age 57.5±11.6 years, 74% radiological stage IV). 97 (77%) received...
Background Viral respiratory infections are the main causes of asthma exacerbation. The susceptibility patients with to develop an exacerbation when they present severe pneumonia due acute syndrome coronavirus 2 (SARS-CoV-2) infection is unknown. objective this study was investigate characteristics and outcomes asthmatic disease 2019 (COVID-19) who required hospitalisation during spring 2020 outbreak in Paris, France. Methods A prospective cohort follow-up carried out from 15 March April...
Metallo-β-lactamase (MBL)-producing Gram-negative bacteria are often extremely resistant, leading to a real therapeutic dead end. Here, we evaluated the in vitro and vivo efficacy of aztreonam combination with ceftazidime-avibactam, ceftolozane-tazobactam, or amoxicillin-clavulanate for treatment infections caused by MBL-producing Enterobacteriaceae , Pseudomonas aeruginosa drug-resistant Stenotrophomonas maltophilia .
Rationale: NT-proBNP (N-terminal pro–brain natriuretic peptide), a biomarker of cardiac origin, is used to risk stratify patients with pulmonary arterial hypertension (PAH). Its limitations include poor sensitivity early vascular pathology. Other biomarkers or systemic origin may also be useful in the management PAH. Objectives: Identify prognostic proteins PAH that complement and clinical scores. Methods: An aptamer-based assay (SomaScan version 4) targeting 4,152 was measure plasma...
Activins are novel therapeutic targets in pulmonary arterial hypertension (PAH). We therefore studied whether key members of the activin pathway could be used as PAH biomarkers.
Introduction Pulmonary veno-occlusive disease (PVOD) is a rare and severe subtype of pulmonary arterial hypertension (PAH). Although European Society Cardiology/European Respiratory (ESC/ERS) guidelines advise assessing PAH severity at baseline during follow-up, no existing risk assessment methods have been validated for PVOD. This study aimed to identify prognostic factors, examine the impact treatment strategies evaluate PVOD patients. Methods The analysed all incident patients included in...
Background Haemodynamic variables are prognostic factors in pulmonary arterial hypertension (PAH). However, right heart catheterisation (RHC) is not systematically recommended to assess the risk status during follow-up. This study aimed added value of haemodynamic prevalent patients predict death or lung transplantation according their assessed by non-invasive four-strata model as European guidelines. Methods We evaluated incident with PAH enrolled French registry between 2009 and 2020 who...
The prognostic importance of follow-up haemodynamics and the validity multidimensional risk assessment are not well established for systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH). We assessed incident SSc-PAH patients to determine association between clinical haemodynamic variables at baseline first right heart catheterisation (RHC) with transplant-free survival. RHC included cardiac index, stroke volume index (SVI), compliance vascular resistance. Risk was...
A high prevalence of venous thromboembolism (VTE) has been reported during intensive care unit (ICU) hospitalisation in patients with severe coronavirus disease 2019 (COVID-19) [1, 2]. In most cases, the diagnosis pulmonary embolism (PE) was incidental as underwent computed tomography angiography (CTPA) for aggravation their respiratory condition. Higher mortality is also described D-dimer levels suggesting that VTE complication may contribute to unfavourable prognosis [3, 4]. Even though,...
Previous studies have suggested an association between uric acid (UA) and the severity of pulmonary arterial hypertension (PAH), but it is unknown whether UA contributes to disease pathogenesis. The aim this study was determine prognostic value circulating in era current management PAH investigate role vascular remodelling. Serum levels were determined idiopathic, heritable or anorexigen at baseline first re-evaluation French Pulmonary Hypertension Network. We studied protein xanthine...
The phenotype of pulmonary arterial hypertension (PAH) patients carrying SOX17 pathogenic variants remains mostly unknown.We report the genetic analysis findings, characteristics and outcomes with heritable PAH from French Pulmonary Hypertension Network.20 eight unaffected relatives were identified. median (range) age at diagnosis was 17 (2-53) years, a female:male ratio 1.5. At diagnosis, most (74%) in New York Heart Association Functional Class III or IV severe haemodynamic compromise,...
Background Risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH) are challenged by the lack accurate disease-specific prognostic biomarkers. To date, brain natriuretic peptide (BNP) and/or its N-terminal fragment (NT-proBNP) only markers for right ventricular dysfunction used clinical practice, association echocardiographic invasive haemodynamic variables to predict outcome PAH. Methods This study was designed identify an easily...
Pulmonary veno-occlusive disease (PVOD), also known as “pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement”, is a rare cause PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased vascular resistance right ventricular failure. Environmental risk factors have been associated the development PVOD, such occupational exposure organic solvents chemotherapy, notably mitomycin. PVOD may be mutation in EIF2AK4 gene...